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ABSTRACT
Peripheral blood stem cell transplantation (PBSCT) has been extended to treating hematologic disorders, but
the benefits over bone marrow transplantation (BMT) still remain unclear, especially in nonmalignant hemato-
logic disorders. In this study, we compared class I-II thalassemic children who underwent HLA-matched
PBSCT and BMT for treatment. Conditioning regimens consisted of busulfan and cyclophosphamide, followed
by cyclosporine ± methotrexate for graft-versus-host disease (GVHD) prophylaxis. Using multivariate analysis,
the outcomes of 87 PBSCT patients and 96 BMT patients were reported (median follow-up: 29 and 60 months,
respectively). The median time to neutrophil and platelet recovery in PBSCT patients (11 and 18 days, respec-
tively) was significantly lower than BMT patients (19 and 26 days, respectively) (P\ .001). Grade II-IV acute
GVHD was more frequent in PBSCT versus BMT group (72% versus 55%; P 5 .003) (relative risk 5 1.75,
95% confidence interval [CI]: 1.20-2.57). The incidence of chronic GVHD was more frequent in the PBSCT
versus BMTgroup (48% versus 19%;P\ .001) (relative risk5 2.62, 95%CI: 1.43-4.82). Therewas no difference
in the 2-year overall survival after PBSCT and BMT (83% and 89%, respectively). The 2-year disease-free sur-
vival was 76% in both groups. These results show some advantages of PBSCT, but to improve the risk of GVHD
in PBSCT, a better conditioning and prophylaxis regimen is needed.
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Beta thalassemia is a common genetic disease
worldwide. Supportive therapies such as chronic trans-
fusion for lifetime and iron chelation have ameliorated
clinical manifestations of the disease, but the disease
and treatment-related complications such as liver, car-
diac, endocrine, and posttransfusion viral infections
result in poor quality of life and increased mortality
[1,2].
Bone marrow transplantation (BMT) currently is
the only treatment that offers an effective cure forbeta thalassemia major [3-9]. The vast majority of cen-
ters use bone marrow instead of peripheral blood stem
cells for transplant in thalassemia. In Pesaro, Italy,
.1500 patients have received BMT, with the 20-year
probability of thalassemia-free survival (TFS) around
80%. The updated results strongly suggest that im-
proved outcomes across risk categories is because of
changing supportive cares, conditioning regimens,
and stem cell sources [3-6]. Studies performed by the
European Group for Blood and Marrow Transplanta-
tion (EBMT) and International Bone Marrow301
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malignancies showed that peripheral blood stem cell
transplantation (PBSCT) is better than BMT with re-
gard to hematologic recovery, hospitalization period,
leukemia-free survival, overall survival (OS), and trans-
plant-related mortality (TRM). No significant differ-
ences were seen in grade II to IV acute GVHD
(aGVHD); but the incidence of chronic GVHD
(cGVHD) was significantly higher in the PBSCT
group [10-16]. In a meta analysis involving 15 studies
(9 cohorts, 5 randomized trials, and 1 database review)
a significant increase in the rate of aGVHD (relative
risk [RR] 5 1.16, 95% confidence interval [CI]: 1.04-
1.28) and cGVHD (RR 5 1.57, 95% CI: 1.28-1.98)
was seen in PBSCT compared with BMT. Extensive
cGVHD was less common after BMT; RR 5 0.81
(95% CI: 0.62-1.05) [17]. Other studies have also
showed 22% to 29% of pediatrics involved with
cGVHD [18-21].
Neither decrease of the relapse rate nor decrease of
early TRM could cause prolongation of the OS in the
PBSCT group compared with the BMT group be-
cause of increasing the incidence of cGVHD, which
caused delayed mortality in the PBSCT group [10-
11,13-15,22].
Overall, the studies showed that PBSCT is better
than BMT in high-riskmalignant hematologic disease,
with regard to leukemia-free survival and OS [11-13].
Otherwise, different findings about the incidence of
cGVHD, TRM, and graft rejection may be because
of several impact factors such as study design, number
of patients, underlying disease, preparative regimen,
GVHD prophylaxis regimen, and the follow-up pe-
riod. Other studies have shown that PBSCT is safe
for pediatric donors yielding sufficient stem cells with-
out the risk of anesthesia and blood loss during sur-
gery. However, the risk of cGVHD exists for
pediatric recipients, and may increase morbidity and
mortality [20,23-25].
Until now, few thalassemic patients have been
treated with PBSCT [26,27]. In this study, we evalu-
ated the outcome of a large number of class I and II
beta thalassemia patients treated with PBSCT com-
pared with the BMT. We focused on hematopoietic
recovery, aGVHD and cGVHD, TRM, thalassemia
recurrence, OS, and TFS after the PBSCT with com-
parison to the BMT.
PATIENTS AND METHODS
Patients
In Iran, the first bone marrow transplantation for
thalassemic patients was done in July 1991, and the
first PBSCT was done in December 1997. Our study
was conducted in the BMT ward at Shariati Hospital
in Tehran, and patients with beta thalassemia major
class I and II who received allogeneic transplantationfrom peripheral blood stem cells were enrolled and
compared with a historic control of beta thalassemic
patients in class I and II who received BMT from
HLA-matched donors. All patients and their donors
signed a written informed consent before enroll-
ment.
Inclusion criteria for patients who underwent in
both BMT and PBSCTwere (1) diagnosis of beta thal-
assemia major with Hb electrophoresis, (2) cardiac
ejection fraction of .55%, (3) normal pulmonary
function tests and pulmonary examination, and (4)
liver function tests (LFT) less than twice the upper
limit of normal with normal hepatitis serology test.
According to the Lucarelli classification, if there is
no hepatomegaly, no portal fibrosis, and iron chelation
therapy had been adequate, the patient is in class I; but
if there is hepatomegaly.2 cm in size and/or palpable
or portal fibrosis with or without inadequate chelation
therapy, the patient is in class II.
Patients were excluded if their liver biopsy showed
evidence of liver cirrhosis. All patients were trans-
planted from anHLA-identical sibling donor. The do-
nors had normal physical examinations, normal blood
tests, and negative serology for HIV and hepatitis vi-
ruses.
Conditioning Regimen, GVHD Prophylaxis, and
Stem Cell Collection
The conditioning regimen administered before
transplant included busulfan (BU) 1 mg/kg/dose orally
4 times a day, for 4 consecutive days, and cyclophos-
phamide (CY) 50 mg/kg/day as i.v. infusion for 4 sub-
sequent days without PK adjustment. Methotrexate
(Mtx) and cyclosporine (CsA) were given for the pre-
vention of GVHD. CsA was given either alone as 1.5
mg/kg i.v. twice a day from day 22 to 15 followed
by 6.25 mg/kg orally twice a day, which was tapered
according to the patient’s condition, or in the combi-
nation with Mtx 10 mg/m2 on day 11 and 6 mg/m2
on days 13 and 16.
Bone marrow was collected by the standard tech-
niques from the donor on the day of infusion. The
minimal number of nucleated cells acceptable was 2
 108/kg. In the PBSCT group, the donor was trans-
fused with subcutaneous granulocyte-colony stimulat-
ing factor (G-CSF) at a dose of 10 mg/kg/day for 5
days. Peripheral blood stem cells were collected by
the apheresis procedure on the day of transplantation
for all the patients, and a total of at least 4  108/kg
of the collected nucleated cells of the recipient’s
body weight were infused.
Antibiotics were administered according to the
usual policies for treating febrile neutropenia or
prevention of infections. Patients were treated with
G-CSF only when myeloid engraftment was delayed
or impaired.
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Hematopoietic recovery was defined as absolute
neutrophil count (ANC) count .0.5  109/L and
platelet count .20  109/L without platelet transfu-
sion for 3 consecutive days. Diagnosis of aGVHD
and cGVHD was determined by clinical symptoms
and graded according to IBMTR criteria.
TRM was defined as death because of transplant
complications. TFS was defined as survival in contin-
uous thalassemia free period without any event. OS
was defined as survival with or without thalassemia re-
currence. Recurrence was defined by clinical presenta-
tion in patients who were transfusion dependent and
confirmed by laboratory testing for mixed chimerism
that showed\75% of the donor’s stem cells.
Statistical Analysis
Patients, donors, and transplant characteristics
were compared between groups using chi-square sta-
tistics for discrete variables and Mann-Whitney test
for continuous variables. Probabilities of neutrophil
and platelet (PLT) recovery, incidence of aGVHD
and cGVHD, OS, and TFS were estimated by the Ka-
plan-Meier method and compared between groups
(PBSCT versus BMT) by the log-rank test in a univar-
iate analysis. The Cox proportional hazard regression
model was used for adjusting other potential risk fac-
tors. Proportional hazard assumption was tested for
all risk factors by introducing each variable as a time-
dependent covariate and assessed for significance level
(potential risk factors that were studied are listed in
Table 1). A backward stepwise method was used for
identifying variables significantly associated with the
outcome in the multivariate model. The interaction
between significant covariates and graft type groups
(with significant level P5 .1) entered in each multivar-
iate analysis was examined. The patient and donor’s
age, total number of nucleated cells (TNC), and
mononucleated cells (MNC) were grouped based on
their median in the Cox proportional hazard model.
Analysis of aGVHD and cGVHD on patients who
survived.20 and 80 days after transplantation, respec-
tively, were included. Analysis was performed in
March 2007.
RESULTS
Patients, Donors, and Transplant Characteristics
In this study, 87 patients who received PBSCT
(from December 1997 to January 2007) were com-
pared with 96 patients who underwent BMT (from
July 1991 to November 2005). In the time periods
that some patients received PBSCT or BMT, decision
making on the cell source selection process was
random. However, decisions were also based on thedonor’s ability to undergo apheresis and some restric-
tions.
All the patients in both groups had HLA-matched
sibling donors and received busulfan and cyclophos-
phamide (BUCY) as a conditioning regimen. Patients,
donor, and transplant characteristics are given in
Table 1. Comparison between the groups showed
significant differences in the patient and donors ages,
Table 1. Patients, Donors, and Transplant Characteristics
Group BMT PBSCT P
Number 96 87
Patients
Median age,
year (range)
6 (3-14) 5 (3-16) .020
Sex .048
Male 49 (51) 57 (66)
Female 47 (49) 30 (34)
Class .068
I 40 (42) 48 (55)
II 56 (58) 39 (45)
GVHD prophylaxis .074
CsA alone 26 (27) 34 (39)
CsA 1 Mtx 70 (73) 53 (60)
Median time
to transplantation,
year (range)
4.27 (\1-12) 3.66 (\1-14) .173
Donors
Median age,
year (range)
7 (1-18) 12 (4-27) \.001
Sex .494
Male 49 (51) 40 (46)
Female 47 (49) 47 (54)
Sex-mismatch 44 (46) 47 (54) .268
Female donor
to male recipient
22 (23) 32 (37) .040
ABO-mismatch 63 (66) 54 (62) .617
CMV serology
antibody*
R1/D1 56 (66) 60 (74) .311
R1/D2 6 (7) 4 (5)
R2/D1 8 (9) 10 (12)
R2/D2 15 (18) 7 (9)
TNC infused  108/kg
(range)
4.6 (2.2-13.1) 10.04 (4.3-29.5) \.001
Total MNC infused
108/kg (range)†
2.19 (0.92-4.56) 7.5 (0.89-26.48)\.001
CD341 cells infused
(range)†
2.8 (0.2-10.9) 1.9 (0.1-32.0) \.001
CD31 cells infused
(range)†
17 (2-77) 34.5 (5.0-81.0) \.001
Median follow-up,
month (range)
60 (3-141) 29 (1-76)
GvHD indicates graft-versus-host disease; CsA, cyclosporine; Mtx,
methotrexate; ABO, blood type; CMV, cytomegalovirus; R, re-
cipient; D, donor; TNC, total nucleated cells; MNC, mononu-
cleated cells; BMT, bone marrow transplantation; PBSCT,
peripheral blood stem cell transplantation; (), percent.
*Recipient or donor’s CMV serology test was not available for 6
PBSCT and 11 BMT patients that excluded in P-value calculation.
†MNC,CD341, andCD31were available for 47, 38, and 34 patients
in the BMT group and CD341 and CD31 were available for 67 and
68 patients in the PBSCT group, respectively.
304 A. Ghavamzadeh et al.sex, and female donor-to-male recipient. The patient’s
median age in PBSCT was less than the BMT group
(5 years versus 6 years) (P 5 .02), but the donor’s age
was higher (12 years versus 7 years) (P \ .001). A
higher proportion of PBSCT patients was male (66%
PBSCT versus 51% BMT) (P 5 .048), and received
transplantation from a female donor (37% versus
23%) (P 5 .040). Furthermore, the infused TNC
and MNC, CD31 and CD341 in PBSCT were signif-
icantly more than BMT (P\ .001, for all). No other
significant differences were observed between the 2
groups. Differences between the groups were adjusted
by multivariate analyses.
Hematologic Recovery, Transfusion, and
Hospitalization
The patients who received PBSCT had signifi-
cantly faster recovery of neutrophils and platelets.
The median time to ANC recovery was 11 days (range:
9-40 days) in PBSCT versus 19 days (range: 8-160) in
BMT (P\ .001) (Table 2); similarity, the median time
Table 2. Engraftment, Transplantation, and GVHD
BMT PBSCT P
Median days
of hospitalization (range)*
43 (9-126) 38 (4-131) .098
Median days to
ANC .0.5109/L 19 (8-160) 11 (9-40) \.001
PLT .20109/L 26 (12-210) 18 (1-53) \.001
No. of transfused
RBC unit 5 (1-20) 5 (1-24) .327
Platelet unit 8 (1-38) 5 (1-36) .006
No transfused RBC 1 0
No transfused PLT 1 5
Acute GVHD (No.
of evaluable)
94 82
None 20 (21) 7 (8) .019†
Grade I 21 (28) 15 (21) .287‡
Grade II 33 (45) 31 (41)
Grade III 13 (18) 22 (29)
Grade IV 7 (9) 7 (9)
Chronic GVHD (No.
of evaluable)
90 77
None 73 (82) 40 (52) \.001†
Overall grade .428‡
Limited 13 (76) 23 (62)
Extensive 4 (24) 14 (38)
Recurrence 17 (18) 8 (9) .094
Survival .263
Alive 85 (89) 72 (83)
Death 11 (11) 15 (17)
ANC indicates absolute neutrophil count; PLT, platelet; RBC, red
blood cell; GVHD, graft-versus-host disease; cGVHD, chronic
graft-versus-host disease; aGVHD, acute graft-versus-host dis-
ease; CMV, cytomegalovirus; BMT, bone marrow transplanta-
tion; PBSCT, peripheral blood stem cell transplantation; ():
percent.
*Period of hospitalization calculate from transplantation.
†P-value was related to incidence of aGVHD or cGVHD.
‡P-value was related to aGVHD or cGVHD grading.to PLT recovery was 18 days (range: 1-53 days) in
PBSCT versus 26 days (range: 12-210 days) in BMT
patients (P\ .001) (Table 2).
In the univariate analysis graft type (P\ .001), class
of thalassemia (P5 .005), TNC (P\ .001), and MNC
(P5 .013) were associated with a faster ANC recovery.
In the multivariate analysis only PBSCT and class I
was associated with a shorter time to ANC recovery
(Table 3).
A shorter time to PLT recovery was associated
with graft type (P 5 .003), classification (P 5 .014),
and TNC (P 5 .023) in the univariate analysis. In
the multivariate analysis, class of thalassemia and
Table 3. Multivariate Analysis
Outcome*
Relative Risk
(95% Confidence Interval) P
ANC .0.5  109/L
Graft \.001
BM 1.00
PB 2.98 (2.13-4.15)
Class .023
II 1.00
I 1.44 (1.05-1.98)
PLT .20  109/L†
Graft .011
BM 1.00
PB 1.49 (1.10-2.03)
Class .003
II 1.00
I 1.41(1.03-1.92)
Acute GVHD (grades II-IV)
Graft .004
BM 1.00
PB 1.75(1.20-2.57)
GVHD prophylaxis .022
CsA 1 Mtx 1.00
CsA alone 1.58(1.07-2.34)
Sex-mismatch .024
No 1.00
Yes 1.55(1.06-2.26)
Chronic GVHD
Female donor
to male recipient
.015
No 1.00
Yes 2.00(1.15-3.57)
Graft \.001
BM 1.00
PB 2.62(1.43-4.82)
Acute GVHD (grades III-IV) .003
No 1.00
Yes 2.33(1.33-4.00)
Treatment failure
(recurrence and/or death)
Incidence of acute GVHD .004
Yes 1.00
No 2.65(1.36-5.18)
ANC indicates absolute neutrophil count; BM, bone marrow; PB,
peripheral blood; PLT, platelet; GVHD, graft-versus-host dis-
ease; CsA, cyclosporine; Mtx, methotrexate.
*There were no factors that predict time of death.
†Result of analysis after the mononucleated cells omitted.
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relative risk of TNC .6.5  108/kg was 1.603 (95%
CI: 1.177-2.181; P5 .003) and relative risk of patients
with class I thalassemia was 1.39 (95% CI: 1.021-
1.892; P 5 .036). Because a strong association of
TNC with other factors such as graft type can mask
effects of other risk factors, analysis was performed
again after removing the TNC variable. In the second
analysis, graft type and classification remained as inde-
pendent predictors (Table 3).
The PBSCT group required fewer platelet transfu-
sions than the BMT group (P 5 .006), but there was
not any significant difference in the number of
the red blood cell unit transfusions. The median days
of hospitalization after transplantation was less in
PBSCT than BMT, but no significant difference was
observed (38 versus 43 days, P 5 .098) (Table 2).
GVHD and Performance Status
Incidence and grading of aGVHD are shown in
Table 2. Incidence of aGVHD grades II-IV was 57%
in the BMT group compared with 74% in the PBSCT
group (P 5 .003) (Figure 1). Incidence of aGVHD
grades III-IV was 22% in the BMT group compared
with 36% in PBSCT (P 5 .026). In multivariate anal-
ysis, risk of aGVHD grades II-IV was higher in pa-
tients with each of the following factors: PB graft
type (P 5 .004), GVHD prophylaxis without Mtx (P
5 .023), and sex-mismatched donor and recipient (P
5 .024). Adjusted relative risk for grade II-IV aGVHD
was 1.75 (95% CI: 1.20-2.57, P 5 .004) (Table 3).
Furthermore, cumulative incidence of aGVHD
grades III-IV was significant only for the graft type
(P 5 .034).
Chronic GVHD developed in 19% of the patients
with BMT versus 48% of the patients with PBSCT
(Table 2), whereas extensive cGVHD developed in
4% of the patients with BMT versus 18% of the
PBSCT patients group. Overall grade and severity of
Figure 1. Cumulative incidence of aGVHD grades II-IV.cGVHD did not differ significantly between the
groups, but incidence of cGVHD was strongly related
to the graft type (P\ .001).
Cumulative incidence of cGVHD was related to
the graft type (P \ .001), donor’s age (P 5 .025),
sex-mismatched donor, and recipients (P 5 .046), fe-
male donor-to-male recipient (P 5 .005), TNC (P\
.001), MNC (P 5 .016), prior incidence of aGVHD
(P 5 .014), aGVHD grades II-IV and grades III-IV
(P 5 .013 and P \ .001, respectively) in univariate
analysis. Only the graft type and female donor-to-
male recipient and aGVHD grades III-IV remained
significant in multivariate analysis. Adjusted relative
risk for the incidence of cGVHD among the PBSCT
group was 2.62 (95% CI: 1.43-4.82) times greater
than the BMT group (Table 3). The 1-year cumulative
incidence of cGVHDwas 49% (95%CI: 38% to 62%)
in the PBSCT group compared with 17% (95% CI:
9% to 25%) in the BMT group (Figure 2).
Comparing performance status of the surviving pa-
tients, 83% of the patients after PBSCT had Lansky
score of 90% to 100%; and in the BMT group it was
97%. From 8 of the surviving patients with extensive
cGVHD in the PBSCT group, 5 patients had 90%
Lansky score. In the BMT group, all 4 patients with
extensive cGVHD had 100% Lansky score after their
treatment on their last contact. This difference may be
because of less follow-up and the treatment duration in
the PBSCT patients group (the median of 38 months
versus 52 months follow up for these patients in
PBSCT versus BMT, respectively.)
Causes of Death, TFS, and OS
Causes of death are shown in Table 4. Causes of
death included: aGVHD, cGVHD, infection, idio-
pathic interstitial pneumonia (IPn), multiple organ
failure (not because of GVHD), cardiac toxicity, adult
respiratory distress syndrome (ARDS), and graft fail-
ure. Median follow-up time of surviving patients in
Figure 2. Cumulative incidence of cGVHD.
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the BMT group. There were no factors related to time
of death. Two-year OS was 83% (95% CI: 76%-90%)
versus 89% (95% CI: 83%-95%) after PBSCT and
BMT, respectively; however, it was not significant dif-
ferent (P 5 .125) (Figure 3).
The 1-year cumulative incidence of TRM was
14% in the PBSCT group compared with 9% in the
BMT group (P 5 .123).
Recurrence of thalassemia was detected in 9% and
18% of the patients after PBSCT and BMT, respec-
tively (P5 .094). Although not statistically significant,
recurrence was more apparent in the BMT patients
versus the PBSCT patients. TFS was not statistically
significant between groups (P 5 .786). Two-year
TFS was 76% in both groups (95% CI: 66%-86% in
the PBSCT versus 68%-84% in the BMT group, re-
spectively) (Figure 4).
In multivariate analysis, incidence of aGVHD had
a significant association with a lower risk of treatment
failure (P 5 .004), but significant association was not
observed in aGVHD grades II-IV.
Table 4. Causes of Death
BMT PBSCT
Graft rejection or failure 3 —
Acute GvHD 3 3
Chronic GvHD — 4
Multiple organ failure,
not because of GVHD
1 1
Infection 1 4
ARDS 2 —
Idiopathic interstitial
pneumonia (IPn)
1 2
Cardiac toxicity — 1
Total 11 15
ARDS indicates adult respiratory distress syndrome; BMT, bone
marrow transplantation; PBSCT, peripheral blood stem cell
transplantation.
Figure 3. OS.DISCUSSION
The only curative therapy for patients with thalas-
semia major is allogeneic hematopoietic stem cell
transplantation (HSCT) [3-9]. In a multivariate analy-
sis of the outcome for a large number of patients
treated with BUCY regimen the risk of BMT could
be predicted according to the 3 factors: (1) percent of
hepatomegaly .2 cm, (2) liver fibrosis, and (3) irregu-
lar iron chelation therapy [7,8,28]. TFS and OS in
Class I and II patients prepared with busulfan 4 mg/
kg and cyclophosphomide 200 mg/kg was about 80%
and 90%, respectively [7-9,28].
The largest body of experience in the treatment of
thalassemia with BMT has been reported by Lucarelli
et al. The Pescara experience (Bartolomeo et al. [28])
has reported outcomes of 511 patients\17 years of
age received HLA identical BMT using regimens con-
ditioning by BUCY. The probabilities of TFS, OS,
and TRM for class I and II patients were 87%, 89%,
12%, and 82%, 85%, and 17%, respectively. Graft re-
jection was developed in 10% of the class I and II thal-
assemic patients [28]. Controversy exists regarding
about the use of PBSCT versus BMT as stem cell sour-
ces for SCT in thalassemia.
There are limited studies published with few num-
bers of beta thalassemia major patients who received
PBSCT. Yesilipek et al. [26] treated 15 patients with
beta thalassemia major in different risk classes. The
median neutrophil and platelet engraftment time
were day 12 and 6, respectively. Acute GVHD and
cGVHDwere observed in 26.6% (grade I in 2 patients
and grade II-IV in 2 patients) and 20% of patients, re-
spectively. Two patients died and 13 were well and
transfusion independent 2-30 months after PBSCT.
No recurrence of beta thalassemia has been seen and
OS and disease-free survival (DFS) was 86.6%. Paka-
kasma et al. [27] treated 9 homozygous beta thalasse-
mia and severe beta thalassemia HbE patients with
PBSCT. This study showed that the median time of
Figure 4. TFS.
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reports, which were day 15 and 21, respectively.
Nearly half of the patients developed aGVHD (grade
II, 30% and grade IV, 15%) and 30% developed
cGVHD (limited 2 of 9 and extensive 1 of 9). Neither
graft failure nor graft rejection was observed. The
study concluded that GVHD may be a major compli-
cation in the young age group of patients who under-
went PBSCT [27].
In 2 of the mentioned studies, there are 2 limita-
tions: the small number of patients in the heteroge-
neous clinical class of beta thalassemia major, and the
short period of time in which the outcome of the re-
sults could not be evaluated for PBSCT patients in
class I and II thalassemia.
Our study evaluates the largest group of thalasse-
mic patients receiving PBSCT versus BMT to date.
After adjustment for differences between groups, our
study, similar to previous studies, showed PBSCT in
comparison with BMT was related to more rapid
engraftment in patient undergoing transplant from
an HLA-matched donor.
The median time to ANC and PLT recovery for
PBSCT patient was 11 days and 18 days, respectively.
The PBSCT group required fewer platelet transfu-
sions than the BMT group. The incidence of aGVHD
(grades II-IV) and severe aGVHD (grades III-IV) was
more in the PBSCT group than in the BMT group.
Multivariate analysis showed that PBSCT,GVHD
prophylaxis without Mtx, and sex mismatch donor and
recipient had an increased risk of aGVHD.These find-
ings are consistent with our previously published study
indicating CsA plus short-term Mtx for GVHD pro-
phylaxis, reduces the incidence of aGVHD grades II-
IV independent of other factors [29].
Furthermore, PBSCT in comparison with BMT
has a higher incidence of cGVHD and extensive
cGVHD. The rates of cGVHD and aGVHD seen in
our study are consistent with those reported in the
abovementioned studies. In the univariate analysis,
the cumulative incidence of cGVHD was related to
PBSCT, donor age .10 years, sex mismatched donor
and recipients, TNC .6.5  108 /kg, and prior
aGVHD. Chronic GvHD can lead to increased mor-
tality and morbidity, especially in pediatric recipients.
Studies have suggested that lower incidences of
GVHD may be because of 2 drug GVHD prophylaxis
and ATG used in the conditioning regimen without an
increased risk of thalassemic recurrence [25].
In our study, 4 patients died of cGVHD in the
PBSCT group but none in the BM group (Table 4).
Three patients died in the BMT group from graft re-
jection or failure; none in the PBSCT group died of
this complication. Thalassemia recurrence developed
more in the BMT group than the PBSCT group
(18% versus 9%, respectively) but it was not statisti-
cally significant (P 5 .094).Two-year TFS was 76% in both groups (95% CI:
66%-86% in the PBSCT versus 68%-84% in the
BMT group, respectively). Two-year OS was 83%
(95% CI: 76%-90%) versus 89% (95% CI: 83%-
95%) after PBSCT and BMT, respectively; and it
was not significantly different (P 5 .125).
Although we did not focus on patient’s quality of
life, we observed that the performance status was bet-
ter in the BMT group than the PBSCT group. One ex-
planation may be the higher incidences of extensive
GVHD in the PBSCT compared to the BMT group
(83% of PBSCT patients versus 97% of BMT patients
had a Lansky score of .90%).
In conclusion, our findings show that PBSCT in
thalassemia is associated with earlier engraftment. Al-
though PBSCT may be easier, especially for pediatric
patients, it is associated a higher incidence rate of
aGVHD and cGVHD compared to BMT. In our
study, there was no difference seen in OS or TFS
between the 2 groups. However, this could not reflect
the late deaths because of chronic problems associated
with GVHD. According to previously published
works, 1 alternative is to consider changing the condi-
tioning regimen, prophylaxis regimen or G-CSF-
primed bone marrow as a stem cell source for alloge-
neic bone marrow transplant in children. The use of
ATG in conditioning regimen and sirolimus or tacro-
limus in GVHD prophylaxis for peripheral blood stem
cell transplantation can improve incidence rates of
cGVHD and aGVHD in PBSCT even though the
risk of infections might be increased by this regimen.
Considering the limitations of our study because of
retrospective information, we suggest further studies
using the abovementioned regimens to evaluate the
risks and benefits of PBSCT in thalassemic patients.
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